Hepatitis B virus infection and outcomes of TACE plus lenvatinib and PD-1 inhibitor therapy in unresectable hepatocellular carcinoma: a real-world propensity score-matched study.

Front Immunol · 2026 · PMC13149396 · PMID 42112392

Europe PMC DOI

hedged sentence

0.1180

closest p · 2.4× alpha

0.1180

boldest claim

The sentences

did not reach statistical significanceP = 0.118not close (p > 0.1)

Following PSM, the survival advantage associated with HBV positivity persisted for OS but was attenuated for PFS, which did not reach statistical significance (P = 0.118)( Figures 2G, H ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.